# A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

> **NCT05530655** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Rochester** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer
- Radiation Toxicity
- Urinary Complication

## Interventions

- **DRUG:** Lisinopril Tablets

## Key facts

- **NCT ID:** NCT05530655
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05530655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05530655, "A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05530655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*